These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 8598120)

  • 21. Early detection of gynecologic malignancies.
    Weed JC; Marine CS
    Semin Surg Oncol; 1989; 5(3):176-8. PubMed ID: 2662334
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Occurrence of CA 125 and CA 19-9 tumor-associated antigens in sera of patients with gynecologic, trophoblastic, and colorectal tumors.
    Göcze PM; Szabó DG; Than GN; Csaba IF; Krommer KF
    Gynecol Obstet Invest; 1988; 25(4):268-72. PubMed ID: 2841208
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical evaluation of serum sialosyl-Tn antigen levels in comparison with CA 125 levels in gynecologic cancers.
    Ryuko K; Iwanari O; Nakayama S; Iida K; Kitao M
    Cancer; 1992 May; 69(9):2368-78. PubMed ID: 1562985
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Growing use of nonisotopic CA 19-9 immunoassays increases between-laboratory variability.
    Zucchelli GC; Pilo A; Chiesa MR; Cohen R; Bizollon CA
    Clin Chem; 1993 May; 39(5):909-11. PubMed ID: 8485892
    [No Abstract]   [Full Text] [Related]  

  • 25. Enough evidence to operate?
    Lancet; 1991 May; 337(8749):1066-7. PubMed ID: 1673498
    [No Abstract]   [Full Text] [Related]  

  • 26. [Preparation and characterization of the monoclonal antibodies against human CA15-3 and establishment of a sandwich CLIA system].
    Cao L; Lan X; Wei D; Li Y
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jan; 30(1):66-70. PubMed ID: 24405600
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of Doppler with two-dimensional sonography and CA 125 for prediction of malignancy of pelvic masses.
    Schneider VL; Schneider A; Reed KL; Hatch KD
    Obstet Gynecol; 1993 Jun; 81(6):983-8. PubMed ID: 8497367
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinical evaluation of serum CA-50 and CA 19-9 in gynecological tumors].
    Suzuki M; Ohwada M; Tamada T; Sakurabayashi I; Kawai T
    Rinsho Byori; 1989 Jul; 37(7):784-8. PubMed ID: 2558243
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [CA50].
    Kawabe T
    Nihon Rinsho; 2005 Aug; 63 Suppl 8():645-6. PubMed ID: 16149601
    [No Abstract]   [Full Text] [Related]  

  • 30. [Importance of CA-50 detection in malignant gynecologic tumors].
    Indraccolo SR; Greco A; Cartechini MG; Compagnucci P
    Minerva Ginecol; 1990 Dec; 42(12):507-9. PubMed ID: 2089292
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Heterologous double-determinant immunoradiometric assay CA 125 II: reliable second-generation immunoassay for determining CA 125 in serum.
    Kenemans P; van Kamp GJ; Oehr P; Verstraeten RA
    Clin Chem; 1993 Dec; 39(12):2509-13. PubMed ID: 8252723
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [STN (sialyl Tn antigen)].
    Kannagi R
    Nihon Rinsho; 2005 Aug; 63 Suppl 8():659-62. PubMed ID: 16149605
    [No Abstract]   [Full Text] [Related]  

  • 33. Multiplexed electrochemical immunoassay of biomarkers using metal sulfide quantum dot nanolabels and trifunctionalized magnetic beads.
    Tang D; Hou L; Niessner R; Xu M; Gao Z; Knopp D
    Biosens Bioelectron; 2013 Aug; 46():37-43. PubMed ID: 23500474
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The use of tumor markers in the diagnosis and treatment monitoring of malignant tumors of the female genitalia].
    Seliuzhitskiĭ IV; Skvortsov SV; Lytsar' BN; Khomenko LP
    Akush Ginekol (Mosk); 1993; (4):48-50. PubMed ID: 8250120
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [A clinical evaluation of the CA 72-4 serum level as a possible tumor marker].
    Jibiki K; Takeda M; Abe H; Ito M; Odagiri E; Demura R; Demura H; Takizawa K
    Gan No Rinsho; 1990 Oct; 36(12):2146-52. PubMed ID: 2232183
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Measurement of the soluble membrane receptors for tumor necrosis factor and lymphotoxin in the sera of patients with gynecologic malignancy.
    Grosen EA; Granger GA; Gatanaga M; Ininns EK; Hwang C; DiSaia P; Berman M; Manetta A; Emma D; Gatanaga T
    Gynecol Oncol; 1993 Jul; 50(1):68-77. PubMed ID: 8394276
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinical implication of serum antibody to Thomsen-Friedenreich antigen in patients with gynecological malignancies].
    Yasui T; Sakamoto Y; Ueda T; Maeda N; Shitsukawa K; Furumoto H; Mori K; Daitoh T; Irahara M; Kamada M
    Nihon Sanka Fujinka Gakkai Zasshi; 1988 May; 40(5):583-7. PubMed ID: 3385276
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CA 195 in colorectal cancer.
    Onetto M; Secco GB; Fardelli R; Camerini G; De Salvo L; Ventrella W; Lionetto R
    J Nucl Med Allied Sci; 1990; 34(4 Suppl):123-6. PubMed ID: 2092106
    [No Abstract]   [Full Text] [Related]  

  • 39. The value of preoperative serum CA 125 levels in patients with a pelvic mass.
    Patsner B; Mann WJ
    Am J Obstet Gynecol; 1988 Oct; 159(4):873-6. PubMed ID: 3052078
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sensitive immunoluminometric assay for the detection of procalcitonin.
    Morgenthaler NG; Struck J; Fischer-Schulz C; Bergmann A
    Clin Chem; 2002 May; 48(5):788-90. PubMed ID: 11978614
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.